Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
NEW HAVEN, Conn., March 14, 2018 -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that Dan Wechsler, President and CEO of Melinta, will be presenting at Needham & Company’s 17th Annual Healthcare Conference in New York, NY. Mr. Wechsler’s presentation will take place on Tuesday, March 27, 2018 at 12:45pm Eastern Time. A live and archived webcast of the presentation will be accessible from the Melinta Events & Presentations section of the Investors webpage.
Needham & Company’s Annual Healthcare Conference is host to over 130 public and private companies across the life sciences sectors. It is taking place March 27-28, 2018 at the Westin Grand Central Hotel in New York, NY.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
For More Information:
Media Inquiries:
Amra Maynard
(917) 302-2702
[email protected]
Investor Inquiries:
Lisa DeFrancesco
(847) 681-3217
[email protected]
Raj Mistry
(312) 801-2051
[email protected]
